10-Q: Ligand Pharmaceuticals Reports Q3 2024 Results, Revenue Surges 58% Driven by Royalty and Milestone Growth

Ligand Pharmaceuticals' Q3 2024 revenue increased by 58% year-over-year, driven by strong royalty income and milestone payments, despite a decrease in Captisol sales.

Summary

• Ligand Pharmaceuticals reported a 58% increase in total revenue and other income for the third quarter of 2024, reaching $51.8 million, compared to $32.9 million in the same period of 2023.
• The increase in revenue was primarily driven by a 33% rise in royalties to $31.7 million, due to the acquisition of the QARZIBA royalty stream and increased sales of FILSPARI.
• Captisol sales decreased by 27% to $6.3 million in Q3 2024, compared to $8.6 million in Q3 2023, due to the timing of customer orders.
• Contract revenue and other income saw a significant increase of 3,623% to $13.8 million in Q3 2024, primarily due to a commercial milestone payment related to Verona's Ohtuvayre.
• Operating costs and expenses increased by 53% to $48.7 million in Q3 2024, mainly due to fair value adjustments to partner program derivatives and a one-time stock compensation expense.
• The company reported a net loss of $7.2 million for Q3 2024, compared to a net loss of $10.3 million in Q3 2023.
• For the first nine months of 2024, total revenue and other income increased by 20% to $124.3 million, compared to $103.2 million in the same period of 2023.
• The company's cash, cash equivalents, and short-term investments totaled $219.6 million as of September 30, 2024, an increase of $49.3 million from the end of 2023.
• Ligand has $124.4 million available under its revolving credit facility as of September 30, 2024.

Sentiment

Score: 5

Explanation: The document presents mixed results. While revenue growth is strong, the net loss, impairment charges, and increased operating expenses temper the positive aspects. The company's future outlook is uncertain, and the risks associated with its business model are significant.

Positives

• The company experienced a significant increase in revenue, driven by royalties and milestone payments.
• The acquisition of the QARZIBA royalty stream and increased sales of FILSPARI contributed to the growth in royalties.
• Ligand has a strong cash position and access to a revolving credit facility.
• The company successfully raised capital through an at-the-market equity offering.
• The company has a diversified portfolio of revenue streams.

Negatives

• Captisol sales decreased by 27% in Q3 2024 due to the timing of customer orders.
• Operating costs and expenses increased by 53% in Q3 2024, impacting profitability.
• The company reported a net loss of $7.2 million for Q3 2024.
• The company recorded a $26.2 million impairment loss for the Ovid (Soticlestat) financial royalty asset.
• The company recorded a $7.8 million fair value adjustment to partner program derivatives due to certain Agenus partners discontinuing development of their partnered programs.

Risks

• The company's revenue is dependent on the success of its partners' products.
• Changes in customer orders can impact Captisol sales.
• The company's operating costs and expenses may fluctuate.
• The company's financial results may be affected by changes in the fair value of its investments and derivatives.
• The company is subject to risks related to the development and commercialization of its products.
• The company is subject to legal proceedings, including an ongoing opioid litigation and a breach of contract claim.

Future Outlook

Ligand will host an investor and analyst day on December 10, 2024, to provide an overview of its business model, investment selection process, portfolio progress, and 2025 guidance.

Management Comments

• CEO Todd Davis and other members of Ligand's senior management team will provide an overview of our business model and investment selection process.
• The management team will review the progress of the portfolio including near-term partner milestones.
• The management team will introduce 2025 guidance.

Industry Context

The report highlights Ligand's strategic partnerships with major pharmaceutical companies and its focus on funding midto late-stage drug development, which aligns with the industry trend of outsourcing drug development and leveraging external innovation. The company's diversified portfolio of revenue streams and its focus on acquiring royalty rights in development stage or commercial biopharmaceutical products is a common strategy in the biotech industry.

Comparison to Industry Standards

• Ligand's revenue growth of 58% in Q3 2024 is significantly higher than the average growth rate for the biotechnology industry, which typically ranges from 10% to 20% annually. For example, companies like Royalty Pharma (RPRX) and Healthcare Royalty Partners, which also focus on acquiring royalty streams, have shown more moderate growth rates.
• The decrease in Captisol sales by 27% in Q3 2024 is a concern, as Captisol is a key technology for Ligand. This contrasts with companies like Cyclo Therapeutics (CYTH), which focus on cyclodextrin-based therapies and have shown more stable sales in their core products.
• The increase in operating costs and expenses by 53% in Q3 2024 is higher than the industry average, which typically sees cost increases in the range of 10% to 20%. This is partly due to the fair value adjustment to partner program derivatives and a one-time stock compensation expense. Companies like BioMarin Pharmaceutical (BMRN) and Vertex Pharmaceuticals (VRTX), which are also in the biotech space, have shown more controlled operating expenses.
• The impairment loss of $26.2 million on the soticlestat financial royalty asset is a significant event. This highlights the risk associated with investing in development-stage assets, which is a common challenge in the biotech industry. Companies like Alnylam Pharmaceuticals (ALNY) and Sarepta Therapeutics (SRPT) have also faced similar challenges with clinical trial failures and asset impairments.
• Ligand's cash position of $219.6 million is relatively strong compared to many smaller biotech companies, but it is lower than larger, more established companies like Amgen (AMGN) and Gilead Sciences (GILD). This cash position provides Ligand with the flexibility to pursue acquisitions and strategic investments.

Management Changes

Legal Proceedings

• Ligand is involved in ongoing opioid litigation in the U.S. District Court for the Northern District of Ohio.
• CyDex Pharmaceuticals, Inc. filed a Verified Complaint against Bexson Biomedical, Inc. for breach of contract and misuse of confidential information.

Related Party Transactions

• Ligand's CEO and director, Todd Davis, is a director of Palvella. Mr. Davis recused himself from both board's consideration of the agreement between Ligand and Palvella.

Stakeholder Impact

• Shareholders may be impacted by the company's net loss and the impairment of the soticlestat asset.
• Employees may be impacted by the departure of the President and COO.
• Customers of Captisol may be impacted by fluctuations in sales.
• Partners may be impacted by the company's strategic decisions and financial performance.
• Creditors may be impacted by the company's debt obligations and financial performance.

Next Steps

• Ligand will host an investor and analyst day in Boston on December 10, 2024.
• The company will continue to monitor the performance of its portfolio and pursue strategic acquisitions and investments.
• The company will continue to evaluate the impact of the soticlestat clinical trial results on its financial outlook.
• The company will continue to monitor the commercial launch of Ohtuvayre and FILSPARI.

Key Dates

Keywords

royalties, Captisol, milestone payments, biopharmaceutical, financial royalty assets, Apeiron, FILSPARI, Ohtuvayre, revenue, net loss, acquisition, investment, clinical trials